MetaCap

Jupiter Neurosciences Inc. (JUNS)

NASDAQ: JUNSHealth CareBiotechnology: Pharmaceutical PreparationsUSD

1.24-0.285 (-18.75%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

JUNS stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$22.53
52-week range
1.20 – 97.73
Day range
1.20 – 1.46
Volume / Avg
20.11K / 69.86K
Beta
—

52-week range

$1.20$97.73

JUNS stock today

Shares of Jupiter Neurosciences (JUNS) finished lower on Nov 20 at $1.24, a drop of 18.75% or $0.285 per share, versus the S&P 500's 3.70% decline. Trading was light, with 20.11K shares changing hands, about 29% of the average daily volume. At this level, JUNS sits near the bottom of its 52-week range of $1.20 to $97.73: 98.7% below the high and 2.9% above the low.

Jupiter Neurosciences has posted a net loss over the last twelve months (EPS of -$22.53), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Jupiter Neurosciences

Company profile

Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, engages in the development of therapeutics for central nervous system disorders and rare diseases in the United States and internationally. It operates in two segments, Pharmaceutical Operations and Premium Nutritional Supplements. The company researches and develops JNS115, which is in Phase IIa clinical trial for the treatment of Parkinson's disease; JNS108, which is in Phase II clinical trial for the treatment of mild cognitive impairment/early Alzheimer's disease; JNS102, which is in Phase II clinical trial for the treatment of mucopolysaccharidosis type 1; and JNS107, which is in Phase II clinical trial for the treatment of mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Christer Rosen
Headquarters
Jupiter, FL
Employees
5
IPO year
2024

Financial highlights

Full financials

In fiscal 2025, Jupiter Neurosciences generated $21,796 in revenue, up 0.0% from fiscal 2024. Jupiter Neurosciences reported a net loss of $8.6 million, compared with a loss of $2.4 million a year earlier. Gross margin was 80.6% and operating margin -40873.2%.

Jupiter Neurosciences annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023
Revenue$21.80K$0—
Growth———
Net income$-8.64M$-2.44M$-4.78M
EPS (diluted)$-0.25$-0.08$-0.18

Earnings

Earnings history
Last reported (Sep/2026)
Nov 16, 2026
EPS actual vs est.
$-6.02 vs —

Jupiter Neurosciences peers

Health Care sector
JUNS peer companies
CompanyPrice% ChgMarket capCompare
PRFXPRF Technologies Ltd.0.4758-23.68%$1.66Mvs JUNS
KALAKALA BIO Inc.2.71-10.28%$1.74Mvs JUNS
SBFMSunshine Biopharma Inc.2.23-5.11%$1.84Mvs JUNS
APVOAptevo Therapeutics Inc.0.4041-2.37%$1.40Mvs JUNS
PPBTPurple Biotech Ltd. ADR1.53-4.09%$1.86Mvs JUNS
PPCBPropanc Biopharma Inc.1.78+3.19%$1.87Mvs JUNS
XRTXXORTX Therapeutics Inc.0.839-5.73%$1.88Mvs JUNS
EOCNEocene Ltd.1.78+1.73%$1.90Mvs JUNS

Indexes, lists and sector

Jupiter Neurosciences stock FAQ

What is Jupiter Neurosciences's stock price today?

JUNS last traded at $1.24 as of Nov 20, 4:00 PM EST, down 18.75% on the day. Prices are delayed at least 15 minutes.

Who is Jupiter Neurosciences's CEO?

Mr. Christer Rosen is the chief executive officer of Jupiter Neurosciences Inc., which has about 5 employees.

What is the JUNS 52-week high?

The 52-week high for JUNS is $97.73 and the 52-week low is $1.20. The stock is currently 98.7% below its high.

Compare JUNS